NCI Dictionary of Cancer Terms
anti-VEGFR-2 fully human monoclonal antibody IMC-1121B (AN-tee … ful-ee HYOO-mun MAH-noh-KLOH-nul AN-tee-BAH-dee …)
A drug used with docetaxel to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It is also used alone or with paclitaxel to treat cancer of the stomach or gastroesophageal junction (area where the esophagus connects to the stomach) that is advanced or has spread to other parts of the body. Anti-VEGFR-2 fully human monoclonal antibody IMC-1121B is used in patients whose cancer has gotten worse after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Anti-VEGFR-2 fully human monoclonal antibody IMC-1121B binds to receptors for a protein called vascular endothelial growth factor (VEGF), which may be found on some types of cancer cells. This may prevent the growth of new blood vessels that tumors need to grow. Anti-VEGFR-2 fully human monoclonal antibody IMC-1121B is a type of antiangiogenesis agent and a type of monoclonal antibody. Also called Cyramza, IMC-1121B, and ramucirumab.